Literature DB >> 24272724

Long-term results and subjective outcome after gland-preserving treatment in parotid duct stenosis.

Michael Koch1, Julian Künzel, Heinrich Iro, Georgios Psychogios, Johannes Zenk.   

Abstract

OBJECTIVES/HYPOTHESIS: To assess the objective long-term results and subjective outcome after treatment of Stensen's duct stenosis. STUDY
DESIGN: Retrospective study at a tertiary center.
METHODS: The long-term results after treatment with a minimally invasive regimen focusing on sialendoscopy were assessed in 82 patients with 98 parotid duct stenoses after primary gland-preserving treatment. A questionnaire was used to assess the patients' perception of success, including clinical parameters and a visual analogue scale (VAS) assessing pain, symptoms, and salivary gland-related quality of life (QOL). Patients were invited to present for clinical and ultrasound examinations and sialendoscopy.
RESULTS: The average follow-up period was 98.48 months. Fifty percent of the patients reported having recurrent gland swelling; but only 19.5% reported recurrent pain and the VAS scores for current symptoms and pain were low. Independent of the type of stenosis, the VAS scores showed a significant reduction in symptoms and improvement in the perceived QOL after the treatment (P = 0.0001 each). Follow-up examinations were carried out in 20.73% of the patients, and sialendoscopy was performed in 12.1% of the patients. After diagnosis, recurrent stenoses (n = 8, 9.75%) were successfully reopened in all cases. The glands were preserved in all of the patients.
CONCLUSION: Long-term evaluation after minimally invasive treatment of stenoses of the parotid duct indicates that high success rates, high rates of gland preservation, and an acceptable subjective patient outcome can be achieved.
© 2014 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Salivary gland; Stensen's duct; long-term results; minimally invasive; obstruction; sialendoscopy; stenosis; stricture; treatment

Mesh:

Year:  2014        PMID: 24272724     DOI: 10.1002/lary.24534

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  7 in total

1.  Success of minimally invasive salivary gland surgery-Quality of life, prognostic factors.

Authors:  Frederike Weigelt; Christoph Borzikowsky; Markus Hoffmann; Martin Laudien
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-09-01

2.  Sialoendoscopy as a diagnostic and therapeutic option for obstructive diseases of the large salivary glands-a retrospective analysis.

Authors:  Robert Cordesmeyer; Jan Winterhoff; Philipp Kauffmann; Rainer Laskawi
Journal:  Clin Oral Investig       Date:  2015-09-11       Impact factor: 3.573

3.  The introduction of sialendoscopy has significantly contributed to a decreased number of excised salivary glands in Denmark.

Authors:  Eva Rye Rasmussen; Eva Lykke; Niels Wagner; Troels Nielsen; Stian Waersted; Helge Arndal
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-08-26       Impact factor: 2.503

4.  Botulinum toxin for chronic parotid sialadenitis: A case series and systematic review.

Authors:  Madeleine P Strohl; Chia-Fan Chang; William R Ryan; Jolie L Chang
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-05-02

5.  Outcomes of interventional sialendoscopy for obstructive salivary gland disorders: an Italian multicentre study.

Authors:  A Gallo; P Capaccio; M Benazzo; L De Campora; M De Vincentiis; P Farneti; M Fusconi; M Gaffuri; F Lo Russo; S Martellucci; F Ottaviani; G Pagliuca; G Paludetti; E Pasquini; L Pignataro; R Puxeddu; M Rigante; E Scarano; S Sionis; R Speciale; P Canzi
Journal:  Acta Otorhinolaryngol Ital       Date:  2016-12       Impact factor: 2.124

Review 6.  Sialendoscopy for non-stone disorders: The current evidence.

Authors:  Evren Erkul; M Boyd Gillespie
Journal:  Laryngoscope Investig Otolaryngol       Date:  2016-09-07

Review 7.  Salivary duct stenosis: diagnosis and treatment.

Authors:  M Koch; H Iro
Journal:  Acta Otorhinolaryngol Ital       Date:  2017-04       Impact factor: 2.124

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.